{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/luts-in-men/diagnosis/investigations/","result":{"pageContext":{"chapter":{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations","depth":2,"htmlHeader":"<!-- begin field bf9465e4-ea55-466a-8bd1-aa36174ec200 --><h2>What investigations should I arrange for a man presenting with lower urinary tract symptoms?</h2><!-- end field bf9465e4-ea55-466a-8bd1-aa36174ec200 -->","summary":"","htmlStringContent":"<!-- begin item d2379fb8-8a93-4a8d-b050-858164598cbe --><!-- begin field 25e98697-8e79-4dff-9436-f566a073ae12 --><ul><li><strong>Investigations should be guided by the <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/diagnosis/assessment/\">symptoms, history, and examination</a>.</strong></li><li><strong>Dipstick test the urine </strong>to check for blood, glucose, protein, leucocytes, and nitrites.</li><li><strong>Measure serum creatinine and estimated glomerular filtration rate (eGFR) if clinically indicated, </strong>for example if the man has:<ul><li>Chronic urinary retention — suggested by bedwetting or an enlarged bladder detected on abdominal palpation or percussion.</li><li>Recurrent urinary tract infection.</li><li>History of renal stones.</li></ul></li><li><strong>Consider the need for prostate specific antigen (PSA) testing.</strong><ul><li><strong>PSA testing is indicated:</strong><ul><li>If symptoms suggest bladder outlet obstruction due to benign prostatic enlargement — the test result can guide drug treatment.</li><li>If the man is concerned about prostate cancer or if the prostate feels abnormal on digital rectal examination — the test result can guide assessment of the risk of prostate cancer.</li></ul></li><li><strong>Before PSA testing:</strong><ul><li>Discuss the indications for the test, the <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/diagnosis/investigations/#interpretation-of-prostate-specific-antigen-results\">interpretation</a>, and implications of the result with the man, and consider with the man whether an abnormal result would affect further management choices. </li><li>Provide enough time and information for the man to decide if he wishes to have the test. A helpful patient information leaflet on <a data-hyperlink-id=\"5c67c305-99af-460f-8fd7-aa0f00c86ff0\" href=\"https://prostatecanceruk.org/prostate-information/prostate-tests/psa-test#advantages-disadvantages\">The PSA test</a> can be found on the Prostate Cancer UK website (<a data-hyperlink-id=\"6dc2158c-2b2b-4837-99a9-aa0f00c8701f\" href=\"https://prostatecanceruk.org/\">prostatecanceruk.org</a>).</li></ul></li><li><strong>Delay testing if any of the following causes of a transiently increased serum PSA level are present:</strong><ul><li>An active urinary infection (PSA may remain raised for many months).</li><li>Ejaculation in the previous 48 hours.</li><li>Vigorous exercise in the previous 48 hours.</li><li>A prostate biopsy in the previous 6 weeks.</li></ul></li></ul></li></ul><!-- end field 25e98697-8e79-4dff-9436-f566a073ae12 --><!-- end item d2379fb8-8a93-4a8d-b050-858164598cbe -->","topic":{"id":"fdcce69d-578e-5994-a7c2-84be40932dd8","topicId":"a7bf3f2d-1d9e-47c0-9dd3-26731c4d092b","topicName":"LUTS in men","slug":"luts-in-men","lastRevised":"Last revised in March 2019","chapters":[{"id":"149361eb-636f-59a5-a2e2-b067d629a065","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c7972342-637c-56a9-8783-c1e8314e7fd1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7105be47-f38b-5335-b14d-69db43326579","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes"},{"id":"776566d2-009e-5ebd-ac21-e5605029213a","slug":"update","fullItemName":"Update"}]},{"id":"4c1332b1-3f4f-530f-bb70-d627804caa79","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d434ba09-30c6-5bfc-bb6f-87e952a1b33a","slug":"goals","fullItemName":"Goals"},{"id":"702b01d3-71e8-5daf-a985-3935596391f5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0aef110d-14b4-5ae2-9da0-a07cc4aef9ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fcf6ae7-162e-5b90-84fb-2a79f82d420e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1c91c138-4e44-571e-8ac0-8e62f8dca310","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4fe99a13-4e80-5c28-b091-216c8a8d7f82","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3a98397f-2bc4-5e01-90d6-03d6fbe400c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d41a85e2-c1cb-5198-afc7-7c4fbe28ae24","slug":"definitions","fullItemName":"Definitions"},{"id":"fd0f4942-31d6-517a-a10b-d341e34a2504","slug":"causes-of-luts","fullItemName":"Causes of LUTS"},{"id":"3af3e2a4-26b3-5a77-9e8b-3d393388e624","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c6eecc6-b753-5918-adae-dc2d864d88fa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1432aa0-7841-5eec-85c4-e344d4629bd9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8874a841-31e1-5356-a3f6-7bff9c28c693","slug":"assessment","fullItemName":"Assessment"},{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations"}]},{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d790431-a0c8-5ca1-8143-be639ea2ec02","slug":"voiding-symptoms","fullItemName":"Scenario: Voiding symptoms"},{"id":"b1451e1b-3776-5aa0-94b0-79be5fb01831","slug":"overactive-bladder","fullItemName":"Scenario: Overactive bladder"},{"id":"f4818005-dc3a-52b2-ac5d-d14f0d6ac0db","slug":"nocturnal-polyuria","fullItemName":"Scenario: Nocturnal polyuria"},{"id":"fb3acb54-4d76-5aad-ab1c-7b0b3d9443a3","slug":"stress-urinary-incontinence","fullItemName":"Scenario: Stress urinary incontinence"},{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention"},{"id":"0a3e83b8-a00f-520f-b21f-9ef6cc6440e7","slug":"post-micturition-dribble","fullItemName":"Scenario: Post-micturition dribble"}]},{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors"},{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron"},{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide"},{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin"}]},{"id":"dca797b5-427f-5ed5-94e4-3ad565f628a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e289c42-8089-5739-9683-20c374967578","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"07accac1-c375-54a3-92cc-d2cd8a2bb914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c05a5332-4c79-595e-b066-09dcd9841073","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e5cf2cc-d3d4-5d7d-82a7-3dd1ae3c65d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ea76bd-52d3-5c5a-8d1f-f574eec081bd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"38a45d79-a74f-5ca9-a844-f16ea2c0ab75","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b3152db-f873-5814-b35f-54711f247dff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"63207839-c38d-549c-97cc-951ce6806405","slug":"interpretation-of-prostate-specific-antigen-results","fullItemName":"Interpretation of prostate specific antigen results","depth":3,"htmlHeader":"<!-- begin field cb5886dc-eeb4-488a-a167-561b05473669 --><h3>Interpretation of prostate specific antigen results</h3><!-- end field cb5886dc-eeb4-488a-a167-561b05473669 -->","summary":null,"htmlStringContent":"<!-- begin item 650995a5-4067-4f79-9403-4a51bbc483d2 --><!-- begin field e6cd496c-af3c-4322-bac2-18ec7d87e870 --><ul><li><strong>Prostate specific antigen (PSA) is a glycoprotein produced by normal and cancerous prostate cells.</strong><ul><li>It is secreted by prostate epithelial cells into prostatic fluid, where its function is to liquefy semen and thus allow spermatozoa to move more freely.</li><li>Although PSA is secreted into prostatic fluid and semen, small amounts of PSA are present in blood. </li></ul></li><li><strong>Interpreting PSA results can be difficult because:</strong><ul><li>An increased serum PSA level can be present with:<ul><li>Prostate enlargement.</li><li>Older age (PSA levels normally increase with age).</li><li>Infection (for example prostatitis and urinary tract infection).</li><li>Physical causes, including following vigorous exercise, digital rectal examination, catheterization, and prostate biopsy.</li><li>Prostate cancer.</li><li>A normal prostate.</li></ul></li><li>A normal serum PSA level can be present with:<ul><li>Prostate enlargement.</li><li>Prostate cancer.</li><li>Infection.</li></ul></li><li>A decrease serum PSA level can be present with:<ul><li>The use of certain drugs, including <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/5-alpha-reductase-inhibitors/\">5-alpha reductase inhibitors</a> (a decrease in PSA levels is seen rapidly, within the first few months of treatment), aspirin, statins, and thiazide diuretics.</li><li>Obesity. </li></ul></li></ul></li><li>For detailed information on PSA testing, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/prostate-cancer/diagnosis/psa-testing/\">Information about PSA testing</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/prostate-cancer/\">Prostate cancer</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">National Clinical Guideline Centre, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">PHE, 2016a</a>]</p><!-- end field e6cd496c-af3c-4322-bac2-18ec7d87e870 --><!-- end item 650995a5-4067-4f79-9403-4a51bbc483d2 -->","subChapters":[]},{"id":"72774b8d-5440-56d9-bb0c-ee02e55445ff","slug":"basis-for-recommendation-b80","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field b9e13c93-9816-4aa6-9ab9-b867a2dc1b04 --><h3>Basis for recommendation</h3><!-- end field b9e13c93-9816-4aa6-9ab9-b867a2dc1b04 -->","summary":null,"htmlStringContent":"<!-- begin item b8045c02-22ef-480b-ad2f-f2cd9f55518e --><!-- begin field 17ea7043-e5bf-4c9e-a6a3-b40efcbc90d2 --><p>These recommendations are based largely on the National Institute for Health and Clinical Excellence (NICE) guidelines <em>The management of lower urinary tract symptoms in men </em>(full NICE guideline) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">National Clinical Guideline Centre, 2015</a>] and <em>Lower urinary tract symptoms in men: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">NICE, 2015</a>], and the European Association of Urology (EAU) guideline <em>Management of Non-neurogenic Male LUTS</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">European Association of Urology, 2018</a>].</p><h4>Usefulness of urine dipstick test</h4><ul><li>NICE and the EAU recommend offering men with lower urinary tract symptoms (LUTS) a urine dipstick test to detect conditions such as urinary tract infections (UTI), microhaematuria, and diabetes mellitus [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">National Clinical Guideline Centre, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">European Association of Urology, 2018</a>].</li><li>The general consensus of the EAU is that despite the very limited evidence to support this recommendation, the benefits clearly outweigh the costs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">European Association of Urology, 2018</a>].</li></ul><h4>Assessing renal function</h4><ul><li>NICE recommends offering men with LUTS a serum creatinine test (plus estimated glomerular filtration rate [eGFR] calculation) only if renal impairment is suspected, for example, if the man has a palpable bladder, nocturnal enuresis, recurrent UTI, or a history of renal stones [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">National Clinical Guideline Centre, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">NICE, 2015</a>].</li><li>The EAU recommends assessing renal function if renal impairment is suspected based on history and clinical examination, or in the presence of hydronephrosis, or when considering surgical treatment for male LUTS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">European Association of Urology, 2018</a>].</li></ul><h4>Prostate specific antigen (PSA) testing</h4><ul><li>Expert opinion regarding PSA testing in men varies.</li><li>This recommendation is based on the NICE and EAU guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">National Clinical Guideline Centre, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">NICE, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">European Association of Urology, 2018</a>] and is largely supported by the previous expert reviewers of this CKS topic.<ul><li>NICE recommends PSA testing in men who have symptoms suggesting benign prostatic enlargement, if the prostate feels abnormal on digital examination, or if the man is concerned about prostate cancer and wishes to have a PSA test after discussing the harms and benefits.<ul><li>This recommendation was based on the expert opinion of the NICE guideline development group as data suggesting that PSA has prognostic value in predicting symptom progression were inconsistent. NICE found no relevant studies on the effect of strategies of PSA testing on eventual clinical outcomes.</li></ul></li><li>The EAU recommends PSA testing only if the diagnosis of prostate cancer will change management, or if the PSA result can assist in the treatment and/or decision making process.<ul><li>This recommendation was based on evidence suggesting that PSA has a good predictive value for assessing prostate volume and is a strong predictor of prostate growth. Evidence identified by the EAU also suggests that baseline PSA can predict the risk of acute urinary retention and benign prostatic enlargement-related surgery.</li></ul></li></ul></li><li>The recommendations on when to delay PSA testing are based on the NHS Prostate Cancer Risk Management Programme (PCRMP) documents <em>Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">PHE, 2016a</a>] and <em>Advising well men aged 50 and over about the PSA test for prostate cancer: information for GPs </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">PHE, 2016b</a>].</li></ul><!-- end field 17ea7043-e5bf-4c9e-a6a3-b40efcbc90d2 --><!-- end item b8045c02-22ef-480b-ad2f-f2cd9f55518e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}